O	0	5	Acute
O	6	9	and
O	10	15	Short
O	15	16	-
O	16	20	term
O	21	26	Toxic
O	27	34	Effects
O	35	37	of
B-control	38	52	Conventionally
I-control	53	65	Fractionated
O	66	68	vs
B-intervention	69	85	Hypofractionated
I-intervention	86	91	Whole
I-intervention	91	92	-
I-intervention	92	98	Breast
I-intervention	99	110	Irradiation
O	110	111	:
O	112	113	A
O	114	124	Randomized
O	125	133	Clinical
O	134	139	Trial
O	139	140	.

O	141	144	The
O	145	149	most
O	150	161	appropriate
O	162	166	dose
O	167	180	fractionation
O	181	184	for
O	185	190	whole
O	190	191	-
O	191	197	breast
O	198	209	irradiation
O	210	211	(
O	211	214	WBI
O	214	215	)
O	216	223	remains
O	224	233	uncertain
O	233	234	.

O	235	237	To
O	238	244	assess
O	245	250	acute
O	251	254	and
O	255	256	6
O	256	257	-
O	257	262	month
O	263	268	toxic
O	269	276	effects
O	277	280	and
O	281	288	quality
O	289	291	of
O	292	296	life
O	297	298	(
O	298	301	QOL
O	301	302	)
O	303	307	with
O	308	322	conventionally
O	323	335	fractionated
O	336	339	WBI
O	340	341	(
O	341	343	CF
O	343	344	-
O	344	347	WBI
O	347	348	)
O	349	351	vs
O	352	368	hypofractionated
O	369	372	WBI
O	373	374	(
O	374	376	HF
O	376	377	-
O	377	380	WBI
O	380	381	)
O	381	382	.

O	383	392	Unblinded
O	393	403	randomized
O	404	409	trial
O	410	412	of
O	413	415	CF
O	415	416	-
O	416	419	WBI
O	420	421	(
O	421	422	n
O	423	424	=
B-control-participants	425	428	149
O	428	429	;
O	430	432	50
O	432	433	.
O	433	435	00
O	436	438	Gy
O	438	439	/
O	439	441	25
O	442	451	fractions
O	452	453	+
O	454	459	boost
O	460	461	[
O	461	463	10
O	463	464	.
O	464	466	00
O	466	467	-
O	467	469	14
O	469	470	.
O	470	472	00
O	473	475	Gy
O	475	476	/
O	476	477	5
O	477	478	-
O	478	479	7
O	480	489	fractions
O	489	490	]
O	490	491	)
O	492	494	vs
O	495	497	HF
O	497	498	-
O	498	501	WBI
O	502	503	(
O	503	504	n
O	505	506	=
B-intervention-participants	507	510	138
O	510	511	;
O	512	514	42
O	514	515	.
O	515	517	56
O	518	520	Gy
O	520	521	/
O	521	523	16
O	524	533	fractions
O	534	535	+
O	536	541	boost
O	542	543	[
O	543	545	10
O	545	546	.
O	546	548	00
O	548	549	-
O	549	551	12
O	551	552	.
O	552	554	50
O	555	557	Gy
O	557	558	/
O	558	559	4
O	559	560	-
O	560	561	5
O	562	571	fractions
O	571	572	]
O	572	573	)
O	574	583	following
O	584	590	breast
O	590	591	-
O	591	601	conserving
O	602	609	surgery
O	610	622	administered
O	623	625	in
O	626	635	community
O	635	636	-
O	636	641	based
O	642	645	and
O	646	654	academic
O	655	661	cancer
O	662	669	centers
O	670	672	to
O	673	676	287
O	677	682	women
B-age	683	685	40
I-age	686	691	years
I-age	692	694	or
I-age	695	700	older
B-eligibility	701	705	with
I-eligibility	706	711	stage
I-eligibility	712	713	0
I-eligibility	714	716	to
I-eligibility	717	719	II
I-eligibility	720	726	breast
I-eligibility	727	733	cancer
I-eligibility	734	737	for
I-eligibility	738	742	whom
I-eligibility	743	746	WBI
I-eligibility	747	754	without
I-eligibility	755	763	addition
I-eligibility	764	766	of
I-eligibility	767	768	a
I-eligibility	769	774	third
I-eligibility	775	780	field
I-eligibility	781	784	was
I-eligibility	785	796	recommended
O	796	797	;
O	798	800	76
O	800	801	%
O	802	804	of
O	805	810	study
O	811	823	participants
O	824	825	(
O	825	826	n
O	827	828	=
O	829	832	217
O	832	833	)
O	834	838	were
O	839	849	overweight
O	850	852	or
O	853	858	obese
O	858	859	.

O	860	868	Patients
O	869	873	were
O	874	882	enrolled
O	883	887	from
O	888	896	February
O	897	901	2011
O	902	909	through
O	910	918	February
O	919	923	2014
O	924	927	and
O	928	936	observed
O	937	940	for
O	941	942	a
O	943	950	minimum
O	951	953	of
O	954	955	6
O	956	962	months
O	962	963	.

O	964	978	Administration
O	979	981	of
O	982	984	CF
O	984	985	-
O	985	988	WBI
O	989	991	or
O	992	994	HF
O	994	995	-
O	995	998	WBI
O	998	999	.

O	1000	1009	Physician
O	1009	1010	-
O	1010	1018	reported
O	1019	1024	acute
O	1025	1028	and
O	1029	1030	6
O	1030	1031	-
O	1031	1036	month
O	1037	1042	toxic
O	1043	1050	effects
O	1051	1056	using
O	1057	1065	National
O	1066	1072	Cancer
O	1073	1082	Institute
O	1083	1089	Common
O	1090	1098	Toxicity
O	1099	1107	Criteria
O	1107	1108	,
O	1109	1112	and
O	1113	1120	patient
O	1120	1121	-
O	1121	1129	reported
O	1130	1133	QOL
O	1134	1139	using
O	1140	1143	the
O	1144	1154	Functional
O	1155	1165	Assessment
O	1166	1168	of
O	1169	1175	Cancer
O	1176	1183	Therapy
O	1184	1187	for
O	1188	1196	Patients
O	1197	1201	with
O	1202	1208	Breast
O	1209	1215	Cancer
O	1216	1217	(
O	1217	1221	FACT
O	1221	1222	-
O	1222	1223	B
O	1223	1224	)
O	1224	1225	.

O	1226	1229	All
O	1230	1238	analyses
O	1239	1243	were
O	1244	1253	intention
O	1254	1256	to
O	1257	1262	treat
O	1262	1263	,
O	1264	1268	with
O	1269	1277	outcomes
O	1278	1286	compared
O	1287	1292	using
O	1293	1296	the
O	1297	1298	Ï‡
O	1298	1299	2
O	1300	1304	test
O	1304	1305	,
O	1306	1313	Cochran
O	1313	1314	-
O	1314	1322	Armitage
O	1323	1327	test
O	1327	1328	,
O	1329	1332	and
O	1333	1340	ordinal
O	1341	1349	logistic
O	1350	1360	regression
O	1360	1361	.

O	1362	1364	Of
B-total-participants	1365	1368	287
O	1369	1381	participants
O	1381	1382	,
B-control-participants	1383	1386	149
O	1387	1391	were
O	1392	1402	randomized
O	1403	1405	to
O	1406	1408	CF
O	1408	1409	-
O	1409	1412	WBI
O	1413	1416	and
B-intervention-participants	1417	1420	138
O	1421	1423	to
O	1424	1426	HF
O	1426	1427	-
O	1427	1430	WBI
O	1430	1431	.

O	1432	1441	Treatment
O	1442	1446	arms
O	1447	1451	were
O	1452	1456	well
O	1457	1464	matched
O	1465	1468	for
O	1469	1477	baseline
O	1478	1493	characteristics
O	1493	1494	,
O	1495	1504	including
O	1505	1509	FACT
O	1509	1510	-
O	1510	1511	B
O	1512	1517	total
O	1518	1523	score
O	1524	1525	(
O	1525	1527	HF
O	1527	1528	-
O	1528	1531	WBI
O	1531	1532	,
O	1533	1536	120
O	1536	1537	.
O	1537	1538	1
O	1539	1541	vs
O	1542	1544	CF
O	1544	1545	-
O	1545	1548	WBI
O	1548	1549	,
O	1550	1553	118
O	1553	1554	.
O	1554	1555	8
O	1555	1556	;
O	1557	1558	P
O	1559	1560	=
O	1561	1562	.
O	1562	1564	46
O	1564	1565	)
O	1566	1569	and
O	1570	1580	individual
O	1581	1584	QOL
O	1585	1590	items
O	1591	1595	such
O	1596	1598	as
O	1599	1607	somewhat
O	1608	1610	or
O	1611	1615	more
O	1616	1620	lack
O	1621	1623	of
O	1624	1630	energy
O	1631	1632	(
O	1632	1634	HF
O	1634	1635	-
O	1635	1638	WBI
O	1638	1639	,
O	1640	1642	38
O	1642	1643	%
O	1644	1646	vs
O	1647	1649	CF
O	1649	1650	-
O	1650	1653	WBI
O	1653	1654	,
O	1655	1657	39
O	1657	1658	%
O	1658	1659	;
O	1660	1661	P
O	1662	1663	=
O	1664	1665	.
O	1665	1667	86
O	1667	1668	)
O	1669	1672	and
O	1673	1681	somewhat
O	1682	1684	or
O	1685	1689	more
O	1690	1697	trouble
O	1698	1705	meeting
O	1706	1712	family
O	1713	1718	needs
O	1719	1720	(
O	1720	1722	HF
O	1722	1723	-
O	1723	1726	WBI
O	1726	1727	,
O	1728	1730	10
O	1730	1731	%
O	1732	1734	vs
O	1735	1737	CF
O	1737	1738	-
O	1738	1741	WBI
O	1741	1742	,
O	1743	1745	14
O	1745	1746	%
O	1746	1747	;
O	1748	1749	P
O	1750	1751	=
O	1752	1753	.
O	1753	1755	54
O	1755	1756	)
O	1756	1757	.

O	1758	1765	Maximum
B-outcome	1766	1775	physician
I-outcome	1775	1776	-
I-outcome	1776	1784	reported
I-outcome	1785	1790	acute
I-outcome	1791	1801	dermatitis
O	1802	1803	(
B-iv-bin-percent	1803	1805	36
I-iv-bin-percent	1805	1806	%
O	1807	1809	vs
B-cv-bin-percent	1810	1812	69
I-cv-bin-percent	1812	1813	%
O	1813	1814	;
O	1815	1816	P
O	1817	1818	<
O	1819	1820	.
O	1820	1823	001
O	1823	1824	)
O	1824	1825	,
B-outcome	1826	1834	pruritus
O	1835	1836	(
B-iv-bin-percent	1836	1838	54
I-iv-bin-percent	1838	1839	%
O	1840	1842	vs
B-cv-bin-percent	1843	1845	81
I-cv-bin-percent	1845	1846	%
O	1846	1847	;
O	1848	1849	P
O	1850	1851	<
O	1852	1853	.
O	1853	1856	001
O	1856	1857	)
O	1857	1858	,
B-outcome	1859	1865	breast
I-outcome	1866	1870	pain
O	1871	1872	(
B-iv-bin-percent	1872	1874	55
I-iv-bin-percent	1874	1875	%
O	1876	1878	vs
B-cv-bin-percent	1879	1881	74
I-cv-bin-percent	1881	1882	%
O	1882	1883	;
O	1884	1885	P
O	1886	1887	=
O	1888	1889	.
O	1889	1892	001
O	1892	1893	)
O	1893	1894	,
B-outcome	1895	1912	hyperpigmentation
O	1913	1914	(
B-iv-bin-percent	1914	1915	9
I-iv-bin-percent	1915	1916	%
O	1917	1919	vs
B-cv-bin-percent	1920	1922	20
I-cv-bin-percent	1922	1923	%
O	1923	1924	;
O	1925	1926	P
O	1927	1928	=
O	1929	1930	.
O	1930	1933	002
O	1933	1934	)
O	1934	1935	,
O	1936	1939	and
B-outcome	1940	1947	fatigue
O	1948	1949	(
B-iv-bin-percent	1949	1950	9
I-iv-bin-percent	1950	1951	%
O	1952	1954	vs
B-cv-bin-percent	1955	1957	17
I-cv-bin-percent	1957	1958	%
O	1958	1959	;
O	1960	1961	P
O	1962	1963	=
O	1964	1965	.
O	1965	1967	02
O	1967	1968	)
O	1969	1975	during
O	1976	1987	irradiation
O	1988	1992	were
O	1993	1998	lower
O	1999	2001	in
O	2002	2010	patients
O	2011	2021	randomized
O	2022	2024	to
O	2025	2027	HF
O	2027	2028	-
O	2028	2031	WBI
O	2031	2032	.

O	2033	2036	The
O	2037	2041	rate
O	2042	2044	of
O	2045	2052	overall
B-outcome	2053	2058	grade
I-outcome	2059	2060	2
I-outcome	2061	2063	or
I-outcome	2064	2070	higher
I-outcome	2071	2076	acute
I-outcome	2077	2082	toxic
I-outcome	2083	2090	effects
O	2091	2094	was
O	2095	2099	less
O	2100	2104	with
O	2105	2107	HF
O	2107	2108	-
O	2108	2111	WBI
O	2112	2116	than
O	2117	2121	with
O	2122	2124	CF
O	2124	2125	-
O	2125	2128	WBI
O	2129	2130	(
B-iv-bin-percent	2130	2132	47
I-iv-bin-percent	2132	2133	%
O	2134	2136	vs
B-cv-bin-percent	2137	2139	78
I-cv-bin-percent	2139	2140	%
O	2140	2141	;
O	2142	2143	P
O	2144	2145	<
O	2146	2147	.
O	2147	2150	001
O	2150	2151	)
O	2151	2152	.

O	2153	2156	Six
O	2157	2163	months
O	2164	2169	after
O	2170	2181	irradiation
O	2181	2182	,
O	2183	2193	physicians
O	2194	2202	reported
O	2203	2207	less
B-outcome	2208	2215	fatigue
O	2216	2218	in
O	2219	2227	patients
O	2228	2238	randomized
O	2239	2241	to
O	2242	2244	HF
O	2244	2245	-
O	2245	2248	WBI
O	2249	2250	(
B-iv-bin-percent	2250	2251	0
I-iv-bin-percent	2251	2252	%
O	2253	2255	vs
B-cv-bin-percent	2256	2257	6
I-cv-bin-percent	2257	2258	%
O	2258	2259	;
O	2260	2261	P
O	2262	2263	=
O	2264	2265	.
O	2265	2267	01
O	2267	2268	)
O	2268	2269	,
O	2270	2273	and
O	2274	2282	patients
O	2283	2293	randomized
O	2294	2296	to
O	2297	2299	HF
O	2299	2300	-
O	2300	2303	WBI
O	2304	2312	reported
O	2313	2317	less
B-outcome	2318	2322	lack
I-outcome	2323	2325	of
I-outcome	2326	2332	energy
O	2333	2334	(
B-iv-bin-percent	2334	2336	23
I-iv-bin-percent	2336	2337	%
O	2338	2340	vs
B-cv-bin-percent	2341	2343	39
I-cv-bin-percent	2343	2344	%
O	2344	2345	;
O	2346	2347	P
O	2348	2349	<
O	2350	2351	.
O	2351	2354	001
O	2354	2355	)
O	2356	2359	and
O	2360	2364	less
B-outcome	2365	2372	trouble
I-outcome	2373	2380	meeting
I-outcome	2381	2387	family
I-outcome	2388	2393	needs
O	2394	2395	(
B-iv-bin-percent	2395	2396	3
I-iv-bin-percent	2396	2397	%
O	2398	2400	vs
B-cv-bin-percent	2401	2402	9
I-cv-bin-percent	2402	2403	%
O	2403	2404	;
O	2405	2406	P
O	2407	2408	=
O	2409	2410	.
O	2410	2412	01
O	2412	2413	)
O	2413	2414	.

O	2415	2428	Multivariable
O	2429	2439	regression
O	2440	2449	confirmed
O	2450	2453	the
O	2454	2465	superiority
O	2466	2468	of
O	2469	2471	HF
O	2471	2472	-
O	2472	2475	WBI
O	2476	2478	in
O	2479	2484	terms
O	2485	2487	of
O	2488	2495	patient
O	2495	2496	-
O	2496	2504	reported
O	2505	2509	lack
O	2510	2512	of
O	2513	2519	energy
O	2520	2521	(
O	2521	2525	odds
O	2526	2531	ratio
O	2532	2533	[
O	2533	2535	OR
O	2535	2536	]
O	2536	2537	,
O	2538	2539	0
O	2539	2540	.
O	2540	2542	39
O	2542	2543	;
O	2544	2546	95
O	2546	2547	%
O	2548	2550	CI
O	2550	2551	,
O	2552	2553	0
O	2553	2554	.
O	2554	2556	24
O	2556	2557	-
O	2557	2558	0
O	2558	2559	.
O	2559	2561	63
O	2561	2562	)
O	2563	2566	and
O	2567	2574	trouble
O	2575	2582	meeting
O	2583	2589	family
O	2590	2595	needs
O	2596	2597	(
O	2597	2599	OR
O	2599	2600	,
O	2601	2602	0
O	2602	2603	.
O	2603	2605	34
O	2605	2606	;
O	2607	2609	95
O	2609	2610	%
O	2611	2613	CI
O	2613	2614	,
O	2615	2616	0
O	2616	2617	.
O	2617	2619	16
O	2619	2620	-
O	2620	2621	0
O	2621	2622	.
O	2622	2624	75
O	2624	2625	)
O	2625	2626	.

O	2627	2636	Treatment
O	2637	2641	with
O	2642	2644	HF
O	2644	2645	-
O	2645	2648	WBI
O	2649	2656	appears
O	2657	2659	to
O	2660	2665	yield
O	2666	2671	lower
O	2672	2677	rates
O	2678	2680	of
O	2681	2686	acute
O	2687	2692	toxic
O	2693	2700	effects
O	2701	2705	than
O	2706	2708	CF
O	2708	2709	-
O	2709	2712	WBI
O	2713	2715	as
O	2716	2720	well
O	2721	2723	as
O	2724	2728	less
O	2729	2736	fatigue
O	2737	2740	and
O	2741	2745	less
O	2746	2753	trouble
O	2754	2761	meeting
O	2762	2768	family
O	2769	2774	needs
O	2775	2776	6
O	2777	2783	months
O	2784	2789	after
O	2790	2800	completing
O	2801	2810	radiation
O	2811	2818	therapy
O	2818	2819	.

O	2820	2825	These
O	2826	2834	findings
O	2835	2841	should
O	2842	2844	be
O	2845	2857	communicated
O	2858	2860	to
O	2861	2869	patients
O	2870	2872	as
O	2873	2877	part
O	2878	2880	of
O	2881	2887	shared
O	2888	2896	decision
O	2897	2903	making
O	2903	2904	.
O	2905	2919	clinicaltrials
O	2919	2920	.
O	2920	2923	gov
O	2924	2934	Identifier
O	2934	2935	:
O	2936	2947	NCT01266642
O	2947	2948	.
